Gasperetti Alessio, Peretto Giovanni, Muller Steven A, Hasegawa Kanae, Compagnucci Paolo, Casella Michela, Murray Brittney, Tichnell Crystal, Carrick Richard T, Cadrin-Tourigny Julia, Schiavone Marco, James Cynthia, Amin Ahmad S, Saguner Ardan M, Dello Russo Antonio, Tondo Claudio, Stevenson William, Della Bella Paolo, Calkins Hugh, Tandri Harikrishna
Department of Cardiology, Johns Hopkins University, Baltimore, Maryland, USA; Department of Biomedical Sciences and Public Health, Marche Polytechnic University, Ancona, Italy; Department of Clinical Electrophysiology and Cardiac Pacing, Centro Cardiologico Monzino, IRCCS, Milan, Italy.
Department of Cardiac Electrophysiology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
JACC Clin Electrophysiol. 2024 Mar;10(3):487-498. doi: 10.1016/j.jacep.2023.11.017. Epub 2024 Jan 10.
Desmoplakin (DSP) pathogenic/likely pathogenic (P/LP) variants are associated with malignant phenotypes of arrhythmogenic cardiomyopathy (DSP-ACM). Reports of outcomes after ventricular tachycardia (VT) ablation in DSP-ACM are scarce.
In this study, the authors sought to report on long-term outcomes of VT ablation in DSP-ACM.
Patients with P/LP DSP variants at 9 institutions undergoing VT ablation were included. Demographic, clinical, and instrumental data as well as all ventricular arrhythmia (VA) events were collected. Sustained VAs after the index procedure were the primary outcome. A per-patient before and after ablation comparison of rates of VA episodes per year was performed as well.
Twenty-four DSP-ACM patients (39.3 ± 12.1 years of age, 62.5% male, median 6,116 [Q1-Q3: 3,362-7,760] premature ventricular complexes [PVCs] per 24 hours, median 4 [Q1-Q3: 2-11] previous VA episodes per patient at ablation) were included. Index procedure was most commonly endocardial/epicardial (19/24) The endocardium of the right ventricle (RV), the left ventricle (LV), or both ventricles were mapped in 8 (33.3%), 9 (37.5%), and 7 (29.2%) cases, respectively. Low voltage potentials were found in 10 of 15 patients in the RV and 11 of 16 in the LV. Endocardial ablation was performed in 18 patients (75.0%). Epicardial mapping in 19 patients (79.2%) identified low voltage potentials in 17, and 16 received epicardial ablation. Over the following 2.9 years (Q1-Q3: 1.8-5.5 years), 13 patients (54.2%) experienced VA recurrences. A significant reduction in per-patient event/year before and after ablation was observed (1.4 [Q1-Q3: 0.5-2.4] to 0.1 [Q1-Q3: 0.0-0.4]; P = 0.009). Two patients needed heart transplantation, and 4 died (3 of heart failure and 1 noncardiac death).
VT ablation in DSP-ACM is effective in reducing the VA burden of the disease, but recurrences are common. Most VT circuits are epicardial, with both LV and RV low voltage abnormalities. Heart failure complicates clinical course and is an important cause of mortality.
桥粒斑蛋白(DSP)致病/可能致病(P/LP)变异与致心律失常性心肌病(DSP-ACM)的恶性表型相关。关于DSP-ACM患者室性心动过速(VT)消融术后结局的报道较少。
在本研究中,作者旨在报告DSP-ACM患者VT消融的长期结局。
纳入在9家机构接受VT消融的携带P/LP DSP变异的患者。收集人口统计学、临床和器械检查数据以及所有室性心律失常(VA)事件。首次手术后持续性VA为主要结局。还对每位患者消融前后每年的VA发作率进行了比较。
纳入24例DSP-ACM患者(年龄39.3±12.1岁,男性占62.5%,每24小时室性早搏[PVC]中位数为6116[四分位间距:3362-7760],消融时每位患者既往VA发作中位数为4次[四分位间距:2-11次])。首次手术最常见的是心内膜/心外膜联合消融(19/24)。分别有8例(33.3%)、9例(37.5%)和7例(29.2%)患者对右心室(RV)、左心室(LV)或双心室的心内膜进行了标测。15例RV患者中有10例发现低电压电位,16例LV患者中有11例发现低电压电位。18例患者(75.0%)进行了心内膜消融。19例患者(79.2%)的心外膜标测中有17例发现低电压电位,16例接受了心外膜消融。在接下来的2.9年(四分位间距:1.8-5.5年)中,13例患者(54.2%)出现VA复发。观察到每位患者消融前后每年的事件发生率显著降低(从1.4[四分位间距:0.5-2.4]降至0.1[四分位间距:0.0-0.4];P=0.009)。2例患者需要心脏移植,4例死亡(3例死于心力衰竭,1例死于非心脏原因)。
DSP-ACM患者的VT消融可有效减轻疾病的VA负担,但复发很常见。大多数VT折返环位于心外膜,LV和RV均存在低电压异常。心力衰竭使临床病程复杂化,是死亡的重要原因。